Health ❯ Healthcare

Obesity

Treatment Options Weight Management Weight Loss Weight Loss Treatments Treatment Health Risks Medications Obesity Management Weight Loss Drugs Obesity Treatment

Most Weight Lost on GLP‑1 Drugs Returns Within Two Years After Stopping, Review Finds

Oxford researchers say many users will need ongoing therapy to sustain weight and health gains.

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA Approves First Oral Wegovy Weight-Loss Pill as U.S. Availability Begins

FDA Approves First Oral Weight-Loss GLP-1: Wegovy Pill to Launch in January

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

CHMP Backs Expanded EU Use of Mounjaro for Diabetes in Patients 10+ and Adult Weight Management

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Abdominal Fat, Not BMI, Linked to Harmful Heart Remodeling in MRI Study

WHO Backs GLP-1 Weight-Loss Drugs as New Data Highlight Limits and Unknowns

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

New Survey Finds Insurance Barriers Stalling Bariatric Surgery in India

Stopping GLP-1 Weight-Loss Drugs Before Pregnancy Linked to Higher Gestational Risks, Study Finds

Stopping Mounjaro Leads to Weight Regain and Reversed Health Gains, Study Finds

Denmark Awards Compensation to Four Patients for Eye Damage Linked to Ozempic and Wegovy